A Phase II Study of Topotecan in Patients with Relapsed Small-Cell Lung Cancer
Authors:
- Koji TakedaKTKoji Takeda
- Shunichi NegoroSNShunichi Negoro
- Toshiyuki SawaTSToshiyuki Sawa
- Kazuhiko NakagawaKNKazuhiko Nakagawa
- Masaaki KawaharaMKMasaaki Kawahara
- Takeshi IsobeTITakeshi Isobe
- Shinzoh KudohSKShinzoh Kudoh
- Noriyuki MasudaNMNoriyuki Masuda
- Hisanobu NiitaniHNHisanobu Niitani
- Masahiro FukuokaMFMasahiro Fukuoka
- 1 January 2003
- journal article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 4 (4) , 224-228
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Phase I studies of nogitecan hydrochloride for JapaneseInternational Journal of Clinical Oncology, 2002
- Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung CancerJournal of Clinical Oncology, 1999
- Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.Journal of Clinical Oncology, 1997
- The significance of the sequence of administration of topotecan and etoposideCancer Chemotherapy and Pharmacology, 1996
- American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.Journal of Clinical Oncology, 1994
- Treatment options for patients with relapsed small cell lung cancerLung Cancer, 1993
- Chemotherapy of Lung CancerNew England Journal of Medicine, 1992
- Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activityJournal of Medicinal Chemistry, 1991
- VP-16 and cisplatin as first-line therapy for small-cell lung cancer.Journal of Clinical Oncology, 1985